First results from late-breaking phase III PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration..- Johnson & Johnson.
Johnson & Johnson announced first data from the Phase III PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) or L858R mutations.
Study results showed non-inferior efficacy and pharmacokinetics for SC amivantamab combined with lazertinib compared to intravenous (IV) administration, the currently approved formulation of Rybrevent (amivantamab-vmjw). Administration time for SC amivantamab was reduced to approximately five minutes from five hours (across two days) and showed a five-fold reduction in infusion-related reactions (IRRs). These late-breaking results, which are the Company’s fourth positive Phase III readout for the Rybrevent clinical program, were featured as an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA8505). Data were also selected for the Best of ASCO 2024 Meetings, highlighting the cutting-edge science and leading research in oncology from Johnson & Johnson.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.